ClinicalTrials.gg
RecruitingNCT03812718Updated Apr 27, 2026

Comparison of Anaesthesia Requirement for Ventilation With Endotracheal Tube Versus Proseal Laryngeal Mask Airway

An interventional study of Endotracheal tube (ETT) and ProSeal Laryngeal Mask Airway (PLMA) in Cholelithiases and Cholecystolithiasis, sponsored by Sir Ganga Ram Hospital. Recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Primary conditionCholecystolithiasisRegistry: CholelithiasisReclassifiedWhy we changed it
Registry
Cholelithiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cholecystolithiasis
Why
  1. The study's listed conditions name Cholecystolithiasis, a narrower term within Cholelithiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sir Ganga Ram Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Mar 2019; still recruiting 7 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Endotracheal tube (ETT) is the gold standard conduit for providing controlled ventilation during general anaesthesia (GA). however, the supra-glottic airway (SGA) devices in particular the laryngeal mask airway (LMA) and its variants have become a reliable alternative to ETT for carrying out controlled ventilation. Of the several variants of LMA available today, the proseal LMA (PLMA) is preferred for controlled ventilation. The various advantages of LMA includes, a lower incidence of postoperative sore throat and superior haemodynamic profile during surgery. However, one aspect of providing anaesthesia with LMA compared to ETT is the ability of LMA to maintain equivalent depth of anaesthesia with lower anaesthetic requirement, is quiet intriguing and evidence to this regard is very limited.

By measuring the anaesthesia requirement using a robust computerised delivery system such as the closed loop anaesthesia delivery system (CLADS) we can establish for sure the anaesthesia required for maintaining intraoperative mechanical ventilation with the use of these two (ETT and PLMA) airway management devices.

This randomised controlled study aims to calculate the anaesthesia requirement as determined by the total amount of propofol consumed for maintaining anaesthesia with ETT versus PLMA

Read the detailed description

Endotracheal tube (ETT) is the gold standard conduit for providing controlled ventilation during general anesthesia (GA). However, since the introduction of classic laryngeal mask airway (LMA) in the 1980's and serial evolution of supra-glottic airway devices (SGA) thereafter, LMAs have become a reliable alternative to ETT for carrying out controlled ventilation. Interestingly, of the additional advantages that the LMA proffers, including, a lower incidence of postoperative sore throat (POST) and superior hemodyamic profile during surgery; its ability to maintain equivalent depth of anesthesia (in comparison to when ETT-GA) with lower anesthetic requirement, is intriguing.

A handful of studies have demonstrated that the end-tidal isoflurane concentration required for maintenance of GA is 0.2 -0.53% greater with use of ETT as compared to LMA. However, the evidence generated by these studies remains unsubstantiated because in them, anaesthetic gas concentration was titrated to patient's clinical profile like heart rate and blood pressure without the backing of specific protocol for maintaining depth-of-anaesthesia. Therefore, for credible evidence, assessment of quantitative anesthetic requirement for achieving and sustaining a steady anesthesia depth with either LMA or ETT warrants confirmation with the use of an objective depth-of-anesthesia monitor, such as, bispectral index (BIS).

Closed loop anaesthesia delivery system (CLADS) is an indigenously developed patented (502/DEL/2003) computer-controlled and BIS-guided automated anesthesia delivery system. CLADS, which runs on a control algorithm based on the relationship between diverse rates of propofol infusion and the processed EEG variable; delivers propofol infusion at a rate which is continuously adjusted by patient's state of depth of anesthesia as per BIS monitoring input. This automated system maintains anaesthesia depth with high accuracy and objectively determines propofol delivery quantitatively.

Of the several variants of SGA available today, the ProSeal laryngeal mask airway (PLMA) 9 is preferred for controlled ventilation for its unique design that serves dual function of a ventilation tube and an oropharyngeal drainage tube for excluding gastric contents from getting aspirated through the peri-laryngeal cuff seal.

Given that CLADS can help us to accurately quantify anaesthesia, we hypothesize that there is no difference in anesthesia requirement for GA maintained through an ETT or a PLMA. This randomized controlled study aims to compare: anaesthesia requirement as determined by total propofol consumption (primary objective); intraoperative hemodynamic profile and incidence of POST (secondary objectives) in patients undergoing laparoscopic surgery with controlled ventilation via ETT or PLMA.

02

Conditions studied

  • Cholelithiases
  • Cholecystolithiasis

Browse trials for

03

In context

Cholecystolithiasis Reclassified

88 studies on the registry are indexed under Cholecystolithiasis; 17 are open to participants now.

This study's planned enrollment of 160 is above the median of 100 across 59 interventional studies indexed under Cholecystolithiasis.

Browse Cholecystolithiasis studies →

Lead sponsor

Sir Ganga Ram Hospital is the lead sponsor of 30 studies on the registry; 8 are open to participants now.

Compared within Cholecystolithiasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cholelithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. I/II
  2. Undergoing elective laparoscopic cholecystectomy

Exclusion criteria

Exclusion Criteria:

  1. Anticipated difficult airway
  2. > 30-kg/m2
  3. Uncompensated cardiovascular disease (e.g. uncontrolled hypertension, atrio-ventricular block, sinus bradycardia, congenital heart disease, reduced LV compliance, diastolic dysfunction)
  4. Hepato-renal insufficiency
  5. Uncontrolled endocrinology disease (e.g. diabetes mellitus, hypothyroidism)
  6. Known allergy/ to the study drug (propofol)
  7. Drug dependence/substance abuse/psychiatric illness
  8. Requirement of postoperative ventilation
  9. Refusal to
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    ETT Group

    Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. Intraoperative ventilation will be instituted through a polyvinyl chloride (PVC) ETT (Portex, Smiths Medical ASD, Inc, Minneapolis, USA). The size of the tube will be standardized for the male (7.5 mm ID) and the female (6.5 MM ID).

    Device: Endotracheal tube (ETT)

  • Active comparator
    PLMA Group

    Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. intraoperative ventilation will be maintained with PLMA (Telefex Medical, Westmeath Ireland) whose size would be selected based on body weight. In patients weighing 30-50 kg PLMA # 3.0, 50-70 kg PLMA # 4.0, and 50-100 kg PLMA # 5.0 will be inserted.

    Device: ProSeal Laryngeal Mask Airway (PLMA)

Interventions

  • DeviceEndotracheal tube (ETT)

    After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.

  • DeviceProSeal Laryngeal Mask Airway (PLMA)

    After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.

06

What researchers measure

Primary outcomes

  1. Change in Propofol usage in milligrams

    Comparison of quantitative difference in propofol requirement between the two groups

    Time frame: From beginning of anaesthesia (0-hours, baseline) till 4 hours intraoperatively

Secondary outcomes

  1. Anaesthesia depth consistency using BIS scores

    Determined by the percentage of the total anaesthesia time in which the BIS scores remain within a score of 10% of the target BIS (i.e. BIS-50) in both the study arms.

    Time frame: From beginning of anaesthesia (0-hours, baseline) till 3 hours intraoperatively

  2. Evaluation of propofol anaesthesia delivery system

    Determined by using Varvel criteria parameters; median performance error (MDP), median absolute performance error (MDAPE), wobble and global score in both the study arms

    Time frame: From beginning of anaesthesia (0-hours, baseline) till 3 hours intraoperatively

  3. Change in Intra-operative heart Rate (beats per minute)

    Comparison of intra-operative heart rate between both the arms will be done

    Time frame: From beginning of anaesthesia (0-hours, baseline) till 3 hours intraoperatively

  4. Change in Intra-operative systolic , diastolic, and mean (mmHg)

    Comparison of intra-operative blood pressure- systolic, diastolic, and mean between both the arms will be done

    Time frame: From beginning of anaesthesia (0-hours, baseline) till 10 hours intraoperatively

  5. Early Recovery from anesthesia

    Time taken by the patient to open his/her eyes after discontinuation of anaesthesia will be noted

    Time frame: From end of anaesthesia till 20-minutes postoperatively

  6. Post operative sedation

    Will be assessed using Modified Observer's assessment of alertness/sedation scale (MOAA/S)

    Time frame: From the end of anaesthesia till 24-hours, postoperatively

  7. Incidence of postoperative sore throat

    Comparison of post operative sore throat occurrence between the two groups

    Time frame: From the end of anaesthesia till 24-hours, postoperatively

07

Study locations

1 of 1 sites recruiting
  • Sir Ganga Ram Hospital
    New Delhi, National Capital Territory of Delhi 110060, India
    Recruiting
    • Nitin Sethi, DNB · Contactnitinsethi77@yahoo.co.in · +911142252523
    • Amitabh Dutta, MD · Contactduttaamiatbh@yahoo.co.in · +911142252523
    • Nitin Sethi, DNB · Principal investigator
    • Amitabh Dutta, MD · Principal investigator
    • Goverdhan D Puri, MD,PhD · Principal investigator
    • Jayashree Sood, MD,FFRCA · Sub investigator
    • Bhuwan C Panday, MD · Sub investigator
    • Prabhat K Choudhary, MD · Sub investigator
    • Manish Gupta, MD · Sub investigator
    • Savitar Malhotra, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Nov 2026, 92 months after the start.

Of 27 interventional studies with no phase under Cholecystolithiasis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 92 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2019
First posted
Jan 23, 2019
StartActual
Mar 4, 2019
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03812718
Lead sponsor
Sir Ganga Ram Hospital
Responsible party
Nitin Sethi, DNB (Consultant & Associate Professor, Sir Ganga Ram Hospital) — Principal investigator
First posted
Jan 23, 2019
Start date
Mar 4, 2019
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 27, 2026

Study contacts

Nitin Sethi, DNB
Contact
nitinsethi77@yahoo.co.in
00919717494498
Amitabh Dutta, MD
Contact
duttaamiatbh@yahoo.co.in
+911142252523
Nitin Sethi, DNB
principal investigator · Sir Ganga Ram Hospital
Amitabh Dutta, MD
study director · Sir Ganga Ram Hospital
Jayashree Sood, MD, FFRCA
study chair · Sir Ganga Ram Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion